|
US4399216A
(en)
|
1980-02-25 |
1983-08-16 |
The Trustees Of Columbia University |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
US5179017A
(en)
|
1980-02-25 |
1993-01-12 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
US4634665A
(en)
|
1980-02-25 |
1987-01-06 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
US4475196A
(en)
|
1981-03-06 |
1984-10-02 |
Zor Clair G |
Instrument for locating faults in aircraft passenger reading light and attendant call control system
|
|
US4447233A
(en)
|
1981-04-10 |
1984-05-08 |
Parker-Hannifin Corporation |
Medication infusion pump
|
|
US4439196A
(en)
|
1982-03-18 |
1984-03-27 |
Merck & Co., Inc. |
Osmotic drug delivery system
|
|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
|
US4447224A
(en)
|
1982-09-20 |
1984-05-08 |
Infusaid Corporation |
Variable flow implantable infusion apparatus
|
|
US4487603A
(en)
|
1982-11-26 |
1984-12-11 |
Cordis Corporation |
Implantable microinfusion pump system
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4486194A
(en)
|
1983-06-08 |
1984-12-04 |
James Ferrara |
Therapeutic device for administering medicaments through the skin
|
|
DE3572982D1
(en)
|
1984-03-06 |
1989-10-19 |
Takeda Chemical Industries Ltd |
Chemically modified lymphokine and production thereof
|
|
US4596556A
(en)
|
1985-03-25 |
1986-06-24 |
Bioject, Inc. |
Hypodermic injection apparatus
|
|
US5374548A
(en)
|
1986-05-02 |
1994-12-20 |
Genentech, Inc. |
Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
|
|
MX9203291A
(es)
|
1985-06-26 |
1992-08-01 |
Liposome Co Inc |
Metodo para acoplamiento de liposomas.
|
|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
|
US4941880A
(en)
|
1987-06-19 |
1990-07-17 |
Bioject, Inc. |
Pre-filled ampule and non-invasive hypodermic injection device assembly
|
|
US4790824A
(en)
|
1987-06-19 |
1988-12-13 |
Bioject, Inc. |
Non-invasive hypodermic injection device
|
|
GB8717430D0
(en)
|
1987-07-23 |
1987-08-26 |
Celltech Ltd |
Recombinant dna product
|
|
GB8720833D0
(en)
|
1987-09-04 |
1987-10-14 |
Celltech Ltd |
Recombinant dna product
|
|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
|
GB8809129D0
(en)
|
1988-04-18 |
1988-05-18 |
Celltech Ltd |
Recombinant dna methods vectors and host cells
|
|
US5476996A
(en)
|
1988-06-14 |
1995-12-19 |
Lidak Pharmaceuticals |
Human immune system in non-human animal
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
WO1990006952A1
(fr)
|
1988-12-22 |
1990-06-28 |
Kirin-Amgen, Inc. |
Facteur de stimulation de colonies de granulocytes modifies chimiquement
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5108921A
(en)
|
1989-04-03 |
1992-04-28 |
Purdue Research Foundation |
Method for enhanced transmembrane transport of exogenous molecules
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US5064413A
(en)
|
1989-11-09 |
1991-11-12 |
Bioject, Inc. |
Needleless hypodermic injection device
|
|
US5312335A
(en)
|
1989-11-09 |
1994-05-17 |
Bioject Inc. |
Needleless hypodermic injection device
|
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
DK0710719T3
(da)
|
1990-01-12 |
2007-07-09 |
Amgen Fremont Inc |
Frembringelse af xenogene antistoffer
|
|
US6673986B1
(en)
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
US6172197B1
(en)
|
1991-07-10 |
2001-01-09 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
WO1993012227A1
(en)
|
1991-12-17 |
1993-06-24 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
DE69127627T2
(de)
|
1990-08-29 |
1998-02-19 |
Genpharm Int |
Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
|
|
US5789650A
(en)
|
1990-08-29 |
1998-08-04 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5814318A
(en)
|
1990-08-29 |
1998-09-29 |
Genpharm International Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5877397A
(en)
|
1990-08-29 |
1999-03-02 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US5874299A
(en)
|
1990-08-29 |
1999-02-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US6300129B1
(en)
|
1990-08-29 |
2001-10-09 |
Genpharm International |
Transgenic non-human animals for producing heterologous antibodies
|
|
US6255458B1
(en)
|
1990-08-29 |
2001-07-03 |
Genpharm International |
High affinity human antibodies and human antibodies against digoxin
|
|
CA2061566C
(en)
|
1992-02-20 |
2002-07-09 |
Rudolf E. Falk |
Treatment of disease employing hyaluronic acid and nsaids
|
|
CA2061703C
(en)
|
1992-02-20 |
2002-07-02 |
Rudolf E. Falk |
Formulations containing hyaluronic acid
|
|
ATE408012T1
(de)
|
1991-12-02 |
2008-09-15 |
Medical Res Council |
Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
|
|
CA2130762C
(en)
|
1994-08-24 |
1999-07-06 |
Eva Anne Turley |
Treatment of disease and conditions associated with macrophage infiltration
|
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
|
US5383851A
(en)
|
1992-07-24 |
1995-01-24 |
Bioject Inc. |
Needleless hypodermic injection device
|
|
AU6819494A
(en)
|
1993-04-26 |
1994-11-21 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
WO1994029351A2
(en)
|
1993-06-16 |
1994-12-22 |
Celltech Limited |
Antibodies
|
|
EP0702553A1
(en)
|
1993-12-27 |
1996-03-27 |
BAXTER INTERNATIONAL INC. (a Delaware corporation) |
Water soluble non-immunogenic polyamide cross-linking agents
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6410690B1
(en)
|
1995-06-07 |
2002-06-25 |
Medarex, Inc. |
Therapeutic compounds comprised of anti-Fc receptor antibodies
|
|
US5811097A
(en)
|
1995-07-25 |
1998-09-22 |
The Regents Of The University Of California |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
|
EP0862553A4
(en)
|
1995-10-03 |
1999-02-03 |
Scripps Research Inst |
CBI ANALOG OF CC-1065 AND THE DUOCARMYCINES
|
|
CA2249195A1
(en)
|
1996-03-18 |
1997-09-25 |
Board Of Regents, The University Of Texas System |
Immunoglobin-like domains with increased half lives
|
|
US5834597A
(en)
|
1996-05-20 |
1998-11-10 |
Protein Design Labs, Inc. |
Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
|
|
US5922845A
(en)
|
1996-07-11 |
1999-07-13 |
Medarex, Inc. |
Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
|
|
US7247302B1
(en)
|
1996-08-02 |
2007-07-24 |
Bristol-Myers Squibb Company |
Method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
|
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
AU6703198A
(en)
|
1997-03-21 |
1998-10-20 |
Brigham And Women's Hospital |
Immunotherapeutic ctla-4 binding peptides
|
|
CA2290485C
(en)
|
1997-05-21 |
2008-08-05 |
Biovation Limited |
Method for the production of non-immunogenic proteins
|
|
EP1746107B1
(en)
|
1998-04-02 |
2014-12-17 |
Genentech, Inc. |
Antibody variants and fragments thereof
|
|
ES2292236T3
(es)
|
1998-04-02 |
2008-03-01 |
Genentech, Inc. |
Variantes de anticuerpos y sus fragmentos.
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
DE69942021D1
(de)
|
1998-04-20 |
2010-04-01 |
Glycart Biotechnology Ag |
Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
HK1041274B
(zh)
|
1998-12-23 |
2017-12-01 |
辉瑞大药厂 |
抗ctla-4的人单克隆抗体
|
|
CN1763097B
(zh)
|
1999-01-15 |
2011-04-13 |
杰南技术公司 |
具有改变的效应功能的多肽变体
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
PT1914244E
(pt)
|
1999-04-09 |
2013-07-26 |
Kyowa Hakko Kirin Co Ltd |
Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico
|
|
US20040031072A1
(en)
|
1999-05-06 |
2004-02-12 |
La Rosa Thomas J. |
Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
|
|
CA2944644C
(en)
|
1999-05-07 |
2017-08-22 |
Genentech, Inc. |
Use of rituximab to treat pemphigus
|
|
US20040146516A1
(en)
|
1999-06-17 |
2004-07-29 |
Utah Ventures Ii L.P. |
Lumen-exposed molecules and methods for targeted delivery
|
|
JP4118462B2
(ja)
|
1999-07-19 |
2008-07-16 |
株式会社リコー |
携帯電子機器
|
|
EP1074563A1
(en)
|
1999-08-02 |
2001-02-07 |
F. Hoffmann-La Roche Ag |
Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof
|
|
AU784062B2
(en)
|
1999-08-23 |
2006-01-19 |
Dana-Farber Cancer Institute, Inc. |
Novel B7-4 molecules and uses therefor
|
|
CN1371416B
(zh)
|
1999-08-24 |
2012-10-10 |
梅达里克斯公司 |
人ctla-4抗体及其应用
|
|
CA2384713A1
(en)
|
1999-09-29 |
2001-04-05 |
Human Genome Sciences, Inc. |
Colon and colon cancer associated polynucleotides and polypeptides
|
|
EP3225632B1
(en)
|
1999-11-30 |
2020-05-06 |
Mayo Foundation for Medical Education and Research |
Antibodies binding to b7-h1, a novel immunoregulatory molecule
|
|
DE60040240D1
(de)
|
1999-12-23 |
2008-10-23 |
Zymogenetics Inc |
Löslicher interleukin-20 rezeptor
|
|
DK1616575T3
(da)
|
1999-12-23 |
2012-09-10 |
Zymogenetics Inc |
Fremgangsmåde til behandling af inflammation
|
|
US6610286B2
(en)
|
1999-12-23 |
2003-08-26 |
Zymogenetics, Inc. |
Method for treating inflammation using soluble receptors to interleukin-20
|
|
US20070042392A1
(en)
|
2000-02-03 |
2007-02-22 |
Nuvelo, Inc. |
Novel nucleic acids and polypeptides
|
|
ES2269366T3
(es)
|
2000-02-11 |
2007-04-01 |
Merck Patent Gmbh |
Mejoramiento de la vida media en circulacion de proteinas de fusion basadas en anticuerpos.
|
|
JP2004500412A
(ja)
|
2000-03-31 |
2004-01-08 |
アイデック ファーマスーティカルズ コーポレイション |
Ｂ細胞リンパ腫の治療のための抗サイトカイン抗体またはアンタゴニストおよび抗ｃｄ２０の併用
|
|
HUP0002003A3
(en)
|
2000-05-24 |
2003-01-28 |
Pronuk Biotechnologia Kft |
Process and reagent-kit for determining of 5'-nucleotidase activity
|
|
NO311144B1
(no)
|
2000-05-25 |
2001-10-15 |
Pedersen Viggo Wahl |
Spylemekanisme for vannklosett
|
|
AU2001273224A1
(en)
|
2000-07-07 |
2002-01-21 |
University Of North Carolina At Chapel Hill |
Isolated polynucleotides encoding human 5'-nucleotide cn-ia and cn-ib, isolated proteins encoded by the same, and methods utilizing the same
|
|
ES2564161T3
(es)
|
2000-07-11 |
2016-03-18 |
Research Corporation Technologies, Inc |
Polipéptidos de anticuerpos artificiales
|
|
DE60131456T2
(de)
|
2000-11-30 |
2008-07-10 |
Medarex, Inc., Milpitas |
Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
|
|
WO2002060919A2
(en)
|
2000-12-12 |
2002-08-08 |
Medimmune, Inc. |
Molecules with extended half-lives, compositions and uses thereof
|
|
KR20090010127A
(ko)
|
2001-03-07 |
2009-01-28 |
메르크 파텐트 게엠베하 |
하이브리드 이소타입 항체 부분구조를 포함하는 단백질을 위한 발현 기술
|
|
JP2004532038A
(ja)
|
2001-05-17 |
2004-10-21 |
ディヴァーサ コーポレイション |
新規抗原結合分子の治療、診断、予防、酵素、産業ならびに農業各分野への応用とそのための新規抗原結合分子の作製とスクリーニングの方法
|
|
NZ529788A
(en)
|
2001-05-31 |
2003-12-19 |
Medarex Inc |
Cytotoxins, prodrugs, linkers and stabilizers useful therefor
|
|
BR0213761A
(pt)
|
2001-10-25 |
2005-04-12 |
Genentech Inc |
Composições, preparação farmacêutica, artigo industrializado, método de tratamento de mamìferos, célula hospedeira, método para a produção de uma glicoproteìna e uso da composição
|
|
US6545530B1
(en)
|
2001-12-05 |
2003-04-08 |
Linear Technology Corporation |
Circuit and method for reducing quiescent current in a voltage reference circuit
|
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
|
US20040110226A1
(en)
|
2002-03-01 |
2004-06-10 |
Xencor |
Antibody optimization
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
US20040014194A1
(en)
|
2002-03-27 |
2004-01-22 |
Schering Corporation |
Beta-secretase crystals and methods for preparing and using the same
|
|
IL149820A0
(en)
|
2002-05-23 |
2002-11-10 |
Curetech Ltd |
Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
|
|
CA2495251C
(en)
|
2002-08-14 |
2018-03-06 |
Macrogenics, Inc. |
Fc.gamma.riib-specific antibodies and methods of use thereof
|
|
EP1553975B8
(en)
|
2002-09-27 |
2023-04-12 |
Xencor, Inc. |
Optimized fc variants and methods for their generation
|
|
DE60334141D1
(de)
|
2002-10-15 |
2010-10-21 |
Facet Biotech Corp |
VERÄNDERUNG VON FcRn-BINDUNGSAFFINITÄTEN ODER VON SERUMHALBWERTSZEITEN VON ANTIKÖRPERN MITTELS MUTAGENESE
|
|
AU2004204494B2
(en)
|
2003-01-09 |
2011-09-29 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
WO2004079013A1
(en)
*
|
2003-03-03 |
2004-09-16 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
|
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
|
CN1816356A
(zh)
|
2003-05-14 |
2006-08-09 |
免疫原公司 |
药物缀合物组合物
|
|
CN1829533A
(zh)
|
2003-05-30 |
2006-09-06 |
阿莱克申药物公司 |
包含改造恒定区的抗体和融合蛋白
|
|
AU2004257142A1
(en)
|
2003-05-30 |
2005-01-27 |
Alexion Pharmaceuticals, Inc. |
Antibodies and fusion proteins that include engineered constant regions
|
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
|
WO2005044853A2
(en)
|
2003-11-01 |
2005-05-19 |
Genentech, Inc. |
Anti-vegf antibodies
|
|
US7473531B1
(en)
|
2003-08-08 |
2009-01-06 |
Colora Corporation |
Pancreatic cancer targets and uses thereof
|
|
WO2005019258A2
(en)
|
2003-08-11 |
2005-03-03 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
|
US8883147B2
(en)
|
2004-10-21 |
2014-11-11 |
Xencor, Inc. |
Immunoglobulins insertions, deletions, and substitutions
|
|
US20150071948A1
(en)
|
2003-09-26 |
2015-03-12 |
Gregory Alan Lazar |
Novel immunoglobulin variants
|
|
US8399618B2
(en)
|
2004-10-21 |
2013-03-19 |
Xencor, Inc. |
Immunoglobulin insertions, deletions, and substitutions
|
|
US20060134105A1
(en)
|
2004-10-21 |
2006-06-22 |
Xencor, Inc. |
IgG immunoglobulin variants with optimized effector function
|
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
|
CN103394083B
(zh)
|
2003-11-06 |
2017-07-18 |
西雅图基因公司 |
能够与配体偶联的单甲基缬氨酸化合物
|
|
US20080089892A1
(en)
|
2004-01-12 |
2008-04-17 |
Eli Lilly And Co. |
Fc Region Variants
|
|
US7329353B2
(en)
|
2004-01-23 |
2008-02-12 |
Amgen Inc. |
LC/MS method of analyzing high molecular weight proteins
|
|
WO2005092925A2
(en)
|
2004-03-24 |
2005-10-06 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
|
US7778814B2
(en)
|
2004-03-30 |
2010-08-17 |
Siemens Aktiengesellschaft |
Method and device for simulating an automation system
|
|
NZ550934A
(en)
|
2004-05-19 |
2010-05-28 |
Medarex Inc |
Chemical linkers and conjugates thereof
|
|
RU2402548C2
(ru)
|
2004-05-19 |
2010-10-27 |
Медарекс, Инк. |
Химические линкеры и их конъюгаты
|
|
BRPI0513959A
(pt)
|
2004-07-30 |
2008-05-20 |
Rinat Neuroscience Corp |
anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
|
|
ES2426816T3
(es)
|
2004-08-04 |
2013-10-25 |
Mentrik Biotech, Llc |
Regiones Fc variantes
|
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ｏｘ４０ｌ抗體
|
|
WO2006047350A2
(en)
|
2004-10-21 |
2006-05-04 |
Xencor, Inc. |
IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
|
|
NZ554520A
(en)
|
2004-10-22 |
2010-03-26 |
Amgen Inc |
Methods for refolding of recombinant antibodies
|
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
EA010654B1
(ru)
|
2004-11-23 |
2008-10-30 |
Пи Ай Пи Ко., Лтд. |
Вмонтированная в стену распределительная коробка водоснабжения
|
|
US8716451B2
(en)
|
2005-01-12 |
2014-05-06 |
Kyowa Hakko Kirin Co., Ltd |
Stabilized human IgG2 and IgG3 antibodies
|
|
US7700099B2
(en)
|
2005-02-14 |
2010-04-20 |
Merck & Co., Inc. |
Non-immunostimulatory antibody and compositions containing the same
|
|
US7812135B2
(en)
|
2005-03-25 |
2010-10-12 |
Tolerrx, Inc. |
GITR-binding antibodies
|
|
US7714016B2
(en)
|
2005-04-08 |
2010-05-11 |
Medarex, Inc. |
Cytotoxic compounds and conjugates with cleavable substrates
|
|
AU2006244885B2
(en)
|
2005-05-09 |
2011-03-31 |
E. R. Squibb & Sons, L.L.C. |
Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
|
|
DK2559690T3
(en)
|
2005-05-10 |
2016-04-25 |
Incyte Holdings Corp |
Modulators of indoleamine 2,3-dioxygenase and methods of use thereof
|
|
WO2006130834A2
(en)
|
2005-05-31 |
2006-12-07 |
Board Of Regents, The University Of Texas System |
IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
|
|
AU2006265108C1
(en)
|
2005-07-01 |
2013-01-17 |
E. R. Squibb & Sons, L.L.C. |
Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
|
|
EP1940470B1
(en)
|
2005-09-26 |
2013-04-17 |
Medarex, Inc. |
Antibody-drug conjugates and their use
|
|
WO2007038868A2
(en)
|
2005-10-03 |
2007-04-12 |
The University Of British Columbia |
Novel enediyne compound and uses thereof
|
|
SI1940789T1
(sl)
|
2005-10-26 |
2012-03-30 |
Medarex Inc |
Postopki in spojine za pripravo cc analogov
|
|
US20080206246A1
(en)
|
2006-04-05 |
2008-08-28 |
Ravetch Jeffrey V |
Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
|
|
CA2627190A1
(en)
|
2005-11-10 |
2007-05-24 |
Medarex, Inc. |
Duocarmycin derivatives as novel cytotoxic compounds and conjugates
|
|
ES2540561T3
(es)
|
2005-12-20 |
2015-07-10 |
Incyte Corporation |
N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
|
|
PE20080102A1
(es)
|
2006-05-25 |
2008-02-11 |
Bristol Myers Squibb Co |
Conjugados de analogos de aziridinil-epotilona y composiciones farmaceuticas que comprenden los mismos
|
|
AR061181A1
(es)
|
2006-05-25 |
2008-08-13 |
Bristol Myers Squibb Co |
Compuestos de aziridinil-epotilona
|
|
DE102006027624A1
(de)
|
2006-06-13 |
2007-12-20 |
Elexxion Gmbh |
Handstück für insbesondere medizinische Laseranwendungen
|
|
EP2044123B1
(en)
|
2006-06-21 |
2013-03-13 |
Oncotherapy Science, Inc. |
Tumor-targeting monoclonal antibodies to fzd10 and uses thereof
|
|
US20150030534A1
(en)
|
2013-07-26 |
2015-01-29 |
Rutgers, The State University Of New Jersey |
Antibody cocktails for breast cancer radioimmunotherapy
|
|
WO2008007648A1
(fr)
*
|
2006-07-10 |
2008-01-17 |
Institute For Antibodies Co., Ltd. |
Procédé de classification d'antigène, procédé d'identification d'antigène, procédé d'obtention d' un ensemble d'antigènes ou d'anticorps, procédés de construction d'un panel d'anticorps, anticorps et ens
|
|
CL2007002650A1
(es)
|
2006-09-19 |
2008-02-08 |
Incyte Corp |
Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
|
|
JP5319532B2
(ja)
|
2006-09-19 |
2013-10-16 |
インサイト・コーポレイション |
インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロサイクル
|
|
DK2099823T4
(da)
|
2006-12-01 |
2022-05-09 |
Seagen Inc |
Målbindingsmiddelvarianter og anvendelser deraf
|
|
US8652466B2
(en)
|
2006-12-08 |
2014-02-18 |
Macrogenics, Inc. |
Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
|
|
CL2007003622A1
(es)
|
2006-12-13 |
2009-08-07 |
Medarex Inc |
Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
|
|
TWI412367B
(zh)
|
2006-12-28 |
2013-10-21 |
Medarex Llc |
化學鏈接劑與可裂解基質以及其之綴合物
|
|
TW200900059A
(en)
|
2007-02-21 |
2009-01-01 |
Medarex Inc |
Chemical linkers with single amino acids and conjugates thereof
|
|
JP2008278814A
(ja)
|
2007-05-11 |
2008-11-20 |
Igaku Seibutsugaku Kenkyusho:Kk |
アゴニスティック抗ヒトｇｉｔｒ抗体による免疫制御の解除とその応用
|
|
WO2008147143A2
(en)
|
2007-05-30 |
2008-12-04 |
Postech Academy-Industry Foundation |
Immunoglobulin fusion proteins
|
|
JP5341889B2
(ja)
|
2007-07-17 |
2013-11-13 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
操作された抗αＶインテグリンハイブリッド抗体
|
|
US20090028857A1
(en)
|
2007-07-23 |
2009-01-29 |
Cell Genesys, Inc. |
Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
|
|
DE102007036200A1
(de)
|
2007-08-02 |
2009-02-05 |
Knorr-Bremse Systeme für Nutzfahrzeuge GmbH |
Induktiver Weg- oder Drehwinkelsensor mit zwischen zwei Spulen angeordnetem Abschirmblech
|
|
JP6035009B2
(ja)
|
2007-08-22 |
2016-11-30 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
活性化可能な結合ポリペプチドおよびその同定方法ならびに使用
|
|
JP5963341B2
(ja)
|
2007-09-14 |
2016-08-10 |
アムジエン・インコーポレーテツド |
均質な抗体集団
|
|
TWI563002B
(en)
|
2007-09-26 |
2016-12-21 |
Chugai Pharmaceutical Co Ltd |
Antibody constant region mutant
|
|
MY162534A
(en)
*
|
2007-09-26 |
2017-06-15 |
Chugai Pharmaceutical Co Ltd |
Anti-il-6 receptor antibody
|
|
RU2445366C2
(ru)
|
2007-09-28 |
2012-03-20 |
Чугаи Сейяку Кабусики Кайся |
Антитело против глипикана-3 с улучшенными кинетическими показателями в плазме
|
|
KR101554753B1
(ko)
|
2007-10-01 |
2015-09-22 |
브리스톨-마이어스 스큅 컴퍼니 |
메소텔린에 결합하는 인간 항체 및 이의 용도
|
|
JP5314033B2
(ja)
*
|
2007-10-22 |
2013-10-16 |
メルク セローノ ソシエテ アノニム |
突然変異ＩｇＧＦｃフラグメントと融合した単一ＩＦＮ−ベータ
|
|
FI20070795A0
(fi)
|
2007-10-24 |
2007-10-24 |
Faron Pharmaceuticals Oy |
Uusi biomarkkeri sairauksien kehittämisen tarkkailuun ja terapioiden tehon arviointiin
|
|
US8975081B2
(en)
|
2007-10-24 |
2015-03-10 |
Faron Pharmaceuticals Oy |
Biomarker for monitoring development of diseases and assessing the efficacy of therapies
|
|
CN101918027A
(zh)
|
2007-11-02 |
2010-12-15 |
森托科尔奥索生物科技公司 |
半合成GLP-1肽-Fc融合构造、方法及其用途
|
|
AR069747A1
(es)
|
2007-11-30 |
2010-02-17 |
Medarex Inc |
Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion
|
|
CA2932121A1
(en)
|
2007-11-30 |
2009-06-11 |
Newlink Genetics Corporation |
Ido inhibitors
|
|
KR20100101124A
(ko)
|
2007-11-30 |
2010-09-16 |
브리스톨-마이어스 스큅 컴퍼니 |
단백질 티로신 키나제 ７ (ｐｔｋ７)에 대한 모노클로날 항체 파트너 분자 컨쥬게이트
|
|
EP2808345A3
(en)
|
2007-12-05 |
2015-03-11 |
Massachusetts Institute of Technology |
Aglycosylated immunoglobulin mutants
|
|
KR20160074019A
(ko)
|
2007-12-05 |
2016-06-27 |
추가이 세이야쿠 가부시키가이샤 |
항ｎｒ１０ 항체 및 그의 이용
|
|
HUE024903T2
(en)
|
2007-12-26 |
2016-02-29 |
Xencor Inc |
Fc variants with altered binding to fcrn
|
|
WO2009115652A2
(fr)
|
2008-01-03 |
2009-09-24 |
Universite De La Mediterannee, Aix-Marseille Ii |
Composition et procedes utilisables lors d'un traitement anti-vih
|
|
SI2250279T1
(sl)
|
2008-02-08 |
2016-10-28 |
Medimmune, Llc |
Protitelesa anti-IFNAR1 z zmanjšano afiniteto do FC liganda
|
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
|
AU2009237662A1
(en)
|
2008-04-17 |
2009-10-22 |
Ablynx N.V. |
Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
|
|
CA2975228C
(en)
|
2008-05-02 |
2020-07-21 |
Seattle Genetics, Inc. |
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
WO2010077643A1
(en)
|
2008-12-08 |
2010-07-08 |
Tegopharm Corporation |
Masking ligands for reversible inhibition of multivalent compounds
|
|
PT2376535T
(pt)
|
2008-12-09 |
2017-06-23 |
Hoffmann La Roche |
Anticorpos anti-pd-l1 e a sua utilização para a melhoria do funcionamento das células t
|
|
NZ606427A
(en)
|
2009-02-03 |
2014-10-31 |
Amunix Operating Inc |
Extended recombinant polypeptides and compositions comprising same
|
|
US20120071634A1
(en)
|
2009-03-19 |
2012-03-22 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody Constant Region Variant
|
|
WO2010107110A1
(ja)
|
2009-03-19 |
2010-09-23 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
US20110007023A1
(en)
|
2009-07-09 |
2011-01-13 |
Sony Ericsson Mobile Communications Ab |
Display device, touch screen device comprising the display device, mobile device and method for sensing a force on a display device
|
|
US8394922B2
(en)
|
2009-08-03 |
2013-03-12 |
Medarex, Inc. |
Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
|
|
HUE049825T2
(hu)
|
2009-09-03 |
2020-10-28 |
Merck Sharp & Dohme |
Anti-GITR antitestek
|
|
JP5837821B2
(ja)
|
2009-09-24 |
2015-12-24 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
EP2493862B1
(en)
|
2009-10-28 |
2016-10-05 |
Newlink Genetics Corporation |
Imidazole derivatives as ido inhibitors
|
|
JO3437B1
(ar)
|
2009-10-30 |
2019-10-20 |
Esai R & D Man Co Ltd |
أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
|
|
WO2011066389A1
(en)
|
2009-11-24 |
2011-06-03 |
Medimmmune, Limited |
Targeted binding agents against b7-h1
|
|
US8961967B2
(en)
|
2009-11-30 |
2015-02-24 |
Janssen Biotech, Inc. |
Antibody Fc mutants with ablated effector functions
|
|
MY159679A
(en)
|
2009-12-10 |
2017-01-13 |
Hoffmann La Roche |
Antibodies binding preferentially human csf1r extracellular domain 4 and their use
|
|
SI2954779T1
(sl)
|
2009-12-10 |
2019-06-28 |
Regeneron Pharmaceuticals, Inc. |
Miši, ki proizvajajo težkoverižna protitelesa
|
|
KR101829691B1
(ko)
|
2010-02-08 |
2018-02-19 |
리제너론 파마슈티칼스 인코포레이티드 |
일반적인 경쇄 마우스
|
|
US20120021409A1
(en)
|
2010-02-08 |
2012-01-26 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
|
LT2536745T
(lt)
|
2010-02-19 |
2016-09-26 |
Xencor, Inc. |
Nauji ctla4-ig imunoadhezinai
|
|
BR112012022210B1
(pt)
|
2010-03-04 |
2021-08-17 |
Macrogenics, Inc |
Anticorpo isolado ou seu fragmento imunorreativo, molécula de ácido nucleico, composição farmacêutica, e, uso do anticorpo isolado
|
|
WO2011108714A1
(ja)
|
2010-03-04 |
2011-09-09 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
RU2617971C2
(ru)
|
2010-03-05 |
2017-04-28 |
Ф.Хоффманн-Ля Рош Аг |
Антитела против csf-1r человека и их применение
|
|
MX336682B
(es)
|
2010-03-05 |
2016-01-27 |
Hoffmann La Roche |
Anticuerpos contra csf-1r humanos y usos de los mismos.
|
|
EP3208281A1
(en)
|
2010-03-29 |
2017-08-23 |
Zymeworks, Inc. |
Antibodies with enhanced or suppressed effector function
|
|
EP2558491B1
(en)
|
2010-04-13 |
2018-07-04 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold domain proteins that bind pcsk9
|
|
MX2012011900A
(es)
|
2010-04-15 |
2013-03-21 |
Seattle Genetics Inc |
Conjugados de pirrolobenzodiazepina diana.
|
|
CN102971329B
(zh)
|
2010-04-15 |
2016-06-29 |
麦迪穆有限责任公司 |
用于治疗增殖性疾病的吡咯并苯并二氮杂卓
|
|
US8865653B2
(en)
|
2010-04-22 |
2014-10-21 |
Institut Gustave Roussy |
Method of treatment for immunogenic treatment resistant cancer
|
|
EP2561088A1
(en)
|
2010-04-22 |
2013-02-27 |
Institut Gustave Roussy |
Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
|
|
WO2012007783A1
(en)
|
2010-07-13 |
2012-01-19 |
Institut Gustave Roussy |
Kits and methods for detecting the ability to induce an immunogenic cancer cell death in a subject
|
|
WO2011131472A1
(en)
|
2010-04-22 |
2011-10-27 |
Institut Gustave Roussy |
Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
|
|
WO2011131246A1
(en)
|
2010-04-22 |
2011-10-27 |
Institut Gustave Roussy |
Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
|
|
TW201138808A
(en)
|
2010-05-03 |
2011-11-16 |
Bristol Myers Squibb Co |
Serum albumin binding molecules
|
|
KR20200044999A
(ko)
|
2010-05-04 |
2020-04-29 |
파이브 프라임 테라퓨틱스, 인크. |
Ｃｓｆ1ｒ에 결합하는 항체들
|
|
KR101970944B1
(ko)
|
2010-06-22 |
2019-04-23 |
리제너론 파아마슈티컬스, 인크. |
하이브리드 경쇄 마우스
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
US20130123345A1
(en)
|
2010-07-23 |
2013-05-16 |
The Ohio State University |
Method of treating a viral infection dysfunction by disrupting an adenosine receptor pathway
|
|
AU2011283694B2
(en)
|
2010-07-29 |
2017-04-13 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
|
KR20130136443A
(ko)
|
2010-07-30 |
2013-12-12 |
노파르티스 아게 |
피브로넥틴 크레이들 분자 및 그의 라이브러리
|
|
WO2012031320A1
(en)
|
2010-09-06 |
2012-03-15 |
Peter Maccallum Cancer Institute |
Cancer diagnostic
|
|
SI2614082T1
(sl)
|
2010-09-09 |
2018-12-31 |
Pfizer Inc. |
Molekule, ki vežejo 4-1BB
|
|
EP3708586A1
(en)
|
2010-10-29 |
2020-09-16 |
Perseus Proteomics Inc. |
Anti-cdh3 antibody having high internalization capacity
|
|
CA2824278C
(en)
|
2010-12-20 |
2022-09-20 |
The Rockefeller University |
Modulating agonistic tnfr antibodies
|
|
ES2700514T3
(es)
*
|
2011-02-01 |
2019-02-18 |
Genmab As |
Anticuerpos humanos y conjugados de anticuerpo-fármaco contra CD74
|
|
RU2608504C2
(ru)
|
2011-02-25 |
2017-01-18 |
Чугаи Сейяку Кабусики Кайся |
FcγRIIb-СПЕЦИФИЧНОЕ Fc-АНТИТЕЛО
|
|
EP3144320B9
(en)
|
2011-04-13 |
2018-08-22 |
Bristol-Myers Squibb Company |
Fc fusion proteins comprising novel linkers or arrangements
|
|
NO2694640T3
(enExample)
|
2011-04-15 |
2018-03-17 |
|
|
|
RS57324B1
(sr)
|
2011-04-20 |
2018-08-31 |
Medimmune Llc |
Antitela i drugi molekuli koji vezuju b7-h1 i pd-1
|
|
US8852599B2
(en)
|
2011-05-26 |
2014-10-07 |
Bristol-Myers Squibb Company |
Immunoconjugates, compositions for making them, and methods of making and use
|
|
CA2849039C
(en)
|
2011-09-20 |
2018-09-18 |
Spirogen Sarl |
Pyrrolobenzodiazepines as unsymmetrical dimeric pbd compounds for inclusion in targeted conjugates
|
|
WO2013095738A2
(en)
|
2011-09-27 |
2013-06-27 |
Mapp Biopharmaceutical, Inc. |
Monoclonal antibodies with altered affinities for human fcyri, fcyrllla, and c1q proteins
|
|
ES2402038B1
(es)
|
2011-10-14 |
2013-11-25 |
Josep Ramon Viola Terès |
Base para palé y palé provisto de esta
|
|
WO2013086448A2
(en)
|
2011-12-07 |
2013-06-13 |
Amgen Inc |
IgG2 DISULFIDE ISOFORM SEPARATION
|
|
CN104159921B
(zh)
|
2011-12-15 |
2018-05-04 |
霍夫曼-拉罗奇有限公司 |
针对人csf-1r的抗体及其用途
|
|
EP2793943B1
(en)
|
2011-12-19 |
2018-09-26 |
The Rockefeller University |
Non-sialylated anti-inflammatory polypeptides
|
|
AU2013211824B2
(en)
|
2012-01-27 |
2017-06-01 |
Gliknik Inc. |
Fusion proteins comprising IgG2 hinge domains
|
|
CA2861122A1
(en)
|
2012-02-06 |
2013-08-15 |
Genentech, Inc. |
Compositions and methods for using csf1r inhibitors
|
|
EP2814829B1
(en)
|
2012-02-13 |
2016-12-07 |
Bristol-Myers Squibb Company |
Enediyne compounds, conjugates thereof, and uses and methods therefor
|
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
EP3539984A1
(en)
|
2012-05-11 |
2019-09-18 |
Five Prime Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
|
|
CA3213528A1
(en)
|
2012-05-15 |
2013-11-21 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
|
|
US9943574B2
(en)
|
2012-06-27 |
2018-04-17 |
Arthrogen B.V. |
Combination for treating an inflammatory disorder
|
|
AR091649A1
(es)
|
2012-07-02 |
2015-02-18 |
Bristol Myers Squibb Co |
Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
|
|
TWI713436B
(zh)
|
2012-08-31 |
2020-12-21 |
美商戊瑞治療有限公司 |
用結合群落刺激因子１受體（ｃｓｆ１ｒ）之抗體治療病狀之方法
|
|
NZ628446A
(en)
|
2012-09-13 |
2017-06-30 |
Bristol Myers Squibb Co |
Fibronectin based scaffold domain proteins that bind to myostatin
|
|
KR102215954B1
(ko)
|
2013-02-14 |
2021-02-15 |
브리스톨-마이어스 스큅 컴퍼니 |
튜부리신 화합물, 그의 제조 및 사용 방법
|
|
WO2014153424A1
(en)
|
2013-03-19 |
2014-09-25 |
La Jolla Institute For Allergy And Immunology |
Reducing diabetes in patients receiving hmg-coa reductase inhibitors (statins)
|
|
KR102049991B1
(ko)
|
2013-03-28 |
2019-12-02 |
삼성전자주식회사 |
항 c-Met/항 Her2 이중 특이 항체
|
|
CN103278634B
(zh)
*
|
2013-05-16 |
2015-01-07 |
中国科学院近代物理研究所 |
Cd73作为肾透明细胞癌干细胞表面标志物的应用
|
|
CA3078121A1
(en)
|
2013-09-13 |
2015-03-19 |
Beigene Switzerland Gmbh |
Anti-pd1 antibodies and their use as therapeutics and diagnostics
|
|
EP3508502B1
(en)
|
2013-09-20 |
2023-04-26 |
Bristol-Myers Squibb Company |
Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
|
|
WO2015103072A1
(en)
|
2013-12-30 |
2015-07-09 |
Epimab Biotherapeutics |
Fabs-in-tandem immunoglobulin and uses thereof
|
|
CA2943167A1
(en)
|
2014-03-24 |
2015-10-01 |
University Of Southampton |
Modified antibodies containing modified igg2 domains which elicit agonist or antagonistic properties and use thereof
|
|
US10654884B2
(en)
|
2014-04-25 |
2020-05-19 |
Boehringer Ingelheim International Gmbh |
Purine derivatives as CD73 inhibitors for the treatment of cancer
|
|
SMT201900668T1
(it)
|
2014-06-06 |
2020-01-14 |
Bristol Myers Squibb Co |
Anticorpi contro il recettore per il fattore di necrosi tumorale indotto da glucocorticoidi(gitr)e loro usi
|
|
KR102536786B1
(ko)
|
2014-10-10 |
2023-05-26 |
이나뜨 파르마 에스.에이. |
Ｃｄ７３ 차단
|
|
MY191423A
(en)
|
2014-11-10 |
2022-06-27 |
Medimmune Ltd |
Binding molecules specific for cd73 and uses thereof
|
|
EP3789403A1
(en)
|
2014-11-11 |
2021-03-10 |
MedImmune Limited |
Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof
|
|
EA035766B1
(ru)
|
2014-11-21 |
2020-08-07 |
Бристол-Майерс Сквибб Компани |
Антитело к cd73 и его применения
|
|
BR112017010094A2
(pt)
|
2014-11-21 |
2018-02-06 |
Bristol-Myers Squibb Company |
anticorpos compreendendo regiões constantes de cadeias pesadas modificadas
|
|
KR20180082563A
(ko)
|
2015-11-19 |
2018-07-18 |
브리스톨-마이어스 스큅 컴퍼니 |
글루코코르티코이드-유도된 종양 괴사 인자 수용체 (gitr)에 대한 항체 및 그의 용도
|
|
CN109476740A
(zh)
|
2016-03-04 |
2019-03-15 |
百时美施贵宝公司 |
利用抗cd73抗体的联合治疗
|
|
CN110637035A
(zh)
|
2017-05-25 |
2019-12-31 |
百时美施贵宝公司 |
经修饰的IgG1 Fc结构域与抗-CD40域抗体的融合
|
|
EP3630831B1
(en)
|
2017-05-25 |
2022-06-15 |
Bristol-Myers Squibb Company |
Antagonistic cd40 monoclonal antibodies and uses thereof
|
|
US20200299400A1
(en)
|
2017-05-25 |
2020-09-24 |
Bristol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|
|
BR112020020826A2
(pt)
|
2018-04-12 |
2021-01-19 |
Bristol-Myers Squibb Company |
Terapia de combinação anticâncer com anticorpo antagonista de cd73 e anticorpo antagonista do eixo pd-1/pd-l1
|
|
CN113348177A
(zh)
|
2018-11-28 |
2021-09-03 |
百时美施贵宝公司 |
包含经修饰的重链恒定区的抗体
|